These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26099982)

  • 21. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of PD-1 inhibitors in melanoma management.
    Bowyer S; Lorigan P
    Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
    [No Abstract]   [Full Text] [Related]  

  • 25. Nivolumab plus ipilimumab in the treatment of advanced melanoma.
    Tsai KK; Daud AI
    J Hematol Oncol; 2015 Oct; 8():123. PubMed ID: 26518223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
    Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
    Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
    [No Abstract]   [Full Text] [Related]  

  • 27. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
    J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of primary meningeal melanocytosis treated with combination therapy with nivolumab and ipilimumab.
    Akatsuka T; Toyama T; Morimura S; Komuta M; Mori I; Tanaka T; Tabei Y; Kawashima M; Matsuno A; Sugaya M
    J Dermatol; 2023 Apr; 50(4):e125-e126. PubMed ID: 36440954
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination Immunotherapy for Melanoma.
    Kaufman HL
    JAMA Oncol; 2015 Jun; 1(3):387-8. PubMed ID: 26181189
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
    Spain L; Larkin J
    Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Carlino MS; Long GV
    Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
    Mehta A; Gupta A; Hannallah F; Koshy T; Reimold S
    Melanoma Res; 2016 Jun; 26(3):319-20. PubMed ID: 27110676
    [No Abstract]   [Full Text] [Related]  

  • 35. Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
    Orloff M; Weight R; Valsecchi ME; Sato T
    Rev Recent Clin Trials; 2016; 11(2):81-6. PubMed ID: 27028970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
    Fujisawa Y; Namikawa K; Yoshino K; Kiniwa Y; Ito T; Kato H; Matsushita S; Hoashi T; Nakamura Y; Yoshikawa S; Miyagawa T; Asai J; Matsuya T; Fukushima S; Kato J; Takenouchi T; Uchi H; Masuzawa M; Yanagi T; Maekawa T
    Br J Dermatol; 2023 Jul; 189(2):223-250. PubMed ID: 37017027
    [No Abstract]   [Full Text] [Related]  

  • 37. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dynamics of medical care in skin cancers.
    Dummer R
    Curr Opin Oncol; 2018 Mar; 30(2):105-106. PubMed ID: 29303788
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
    J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.